Corient Private Wealth’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$764M Sell
636,575
-18,212
-3% -$18.6M 0.99% 14
2026
Q1
$615M Sell
654,787
-31,137
-5% -$31.6M 0.88% 17
2025
Q4
$737M Buy
685,924
+196,194
+40% +$188M 1% 16
2025
Q3
$373M Sell
489,730
-130,396
-21% -$97M 0.59% 25
2025
Q2
$483M Buy
620,126
+20,698
+3% +$16.1M 0.64% 22
2025
Q1
$495M Buy
599,428
+23,225
+4% +$19.3M 0.81% 20
2024
Q4
$443M Sell
576,203
-45,307
-7% -$37.5M 0.73% 22
2024
Q3
$551M Buy
621,510
+16,578
+3% +$14.9M 0.86% 20
2024
Q2
$548M Sell
604,932
-51,385
-8% -$41.1M 0.96% 17
2024
Q1
$511M Sell
656,317
-19,171
-3% -$13.6M 0.91% 16
2023
Q4
$394M Buy
675,488
+128,049
+23% +$74.7M 0.72% 27
2023
Q3
$294M Sell
547,439
-41,793
-7% -$21.5M 0.68% 29
2023
Q2
$276M Buy
589,232
+78,215
+15% +$32.8M 0.64% 31
2023
Q1
$176M Buy
511,017
+172,733
+51% +$58.3M 0.47% 49
2022
Q4
$124M Buy
+338,284
New +$120M 0.45% 56

Other funds holding LLY

Corient Private Wealth's LLY Position: Q2 2026 in Review

Corient Private Wealth reduced its Eli Lilly (LLY) stake by 2.8% in Q2 2026, selling an estimated $18.6M and leaving 636,575 shares worth $764M. The position accounts for 0.99% of the portfolio, ranked #14.

Corient Private Wealth first reported a position in LLY in Q4 2022 and has held it in 15 quarters since. 4,614 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Corient Private Wealth held 636,575 shares of Eli Lilly worth $764M as of Q2 2026.
  • Corient Private Wealth sold 18,212 Eli Lilly shares in Q2 2026, an estimated $18.6M.
  • Eli Lilly made up 0.99% of Corient Private Wealth's portfolio in Q2 2026, its #14 holding.
  • Corient Private Wealth first reported a position in Eli Lilly in Q4 2022 and has held it in 15 quarters since.
  • 4,614 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.